首页>
外国专利>
PROCESS FOR PRODUCING A MONOPHASIC PHARMACEUTICAL PRODUCT FOR LIMITING/REDUCING THE RISK OF DEEP VEIN THROMBOSIS UNITED WITH ORAL CONTRACEPTION
PROCESS FOR PRODUCING A MONOPHASIC PHARMACEUTICAL PRODUCT FOR LIMITING/REDUCING THE RISK OF DEEP VEIN THROMBOSIS UNITED WITH ORAL CONTRACEPTION
展开▼
机译:生产用于限制/降低口服避孕药引起的深静脉血栓形成的单相药物产品的方法
展开▼
页面导航
摘要
著录项
相似文献
摘要
Single-phase oral contraceptives containing a combination of 2.0 mg of dienogest and 0.030 mg of ethinylestradiol or 2.0 mg of dienogest and 0.020 mg of ethinylestradiol in nx21 daily dose units followed by nx21 of at the most 7 daily hormone-free or placebo-containing dose units, where n equals 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 and 17, bring about a limitation/reduction of the risk of deep venous thrombosis in combination with oral contraception. A suitable contraceptive agent with a prolonged intake period of the hormone-containing daily dose units is provided which despite the prolonged intake period keeps the risk of a deep venous thrombosis at the same level as with a conventional oral contraceptive and thus within reasonable limits.
展开▼